Arizona State Retirement System Buys 185 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Arizona State Retirement System grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 31,224 shares of the biopharmaceutical company’s stock after acquiring an additional 185 shares during the quarter. Arizona State Retirement System’s holdings in Regeneron Pharmaceuticals were worth $22,242,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Howe & Rusling Inc. raised its stake in Regeneron Pharmaceuticals by 3.4% during the 3rd quarter. Howe & Rusling Inc. now owns 462 shares of the biopharmaceutical company’s stock valued at $486,000 after purchasing an additional 15 shares during the period. Willner & Heller LLC increased its stake in Regeneron Pharmaceuticals by 3.9% in the 4th quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company’s stock worth $284,000 after acquiring an additional 15 shares during the last quarter. OLD Second National Bank of Aurora increased its stake in Regeneron Pharmaceuticals by 0.5% in the 4th quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company’s stock worth $2,025,000 after acquiring an additional 15 shares during the last quarter. Sigma Planning Corp increased its stake in Regeneron Pharmaceuticals by 4.1% in the 3rd quarter. Sigma Planning Corp now owns 409 shares of the biopharmaceutical company’s stock worth $430,000 after acquiring an additional 16 shares during the last quarter. Finally, GLOBALT Investments LLC GA increased its stake in Regeneron Pharmaceuticals by 1.5% in the 3rd quarter. GLOBALT Investments LLC GA now owns 1,067 shares of the biopharmaceutical company’s stock worth $1,122,000 after acquiring an additional 16 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Oppenheimer reduced their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. TD Cowen reduced their price objective on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research note on Tuesday, February 4th. Canaccord Genuity Group downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. Bernstein Bank reduced their price objective on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Finally, Citigroup reduced their price objective on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $687.15 on Thursday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $642.00 and a twelve month high of $1,211.20. The stock has a market capitalization of $75.12 billion, a price-to-earnings ratio of 17.95, a P/E/G ratio of 2.34 and a beta of 0.08. The stock has a fifty day simple moving average of $696.58 and a two-hundred day simple moving average of $857.92. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same period in the prior year, the business earned $11.86 EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.51%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.